Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
4.56
+0.12 (2.70%)
Market open: Aug 12, 2026, 12:38 PM EDT
4.36
-0.03 (-0.68%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Dr. Kanika Chawla Ph.D. | Senior Vice President of Technical Operations (Consultant) |
| Dr. Robert Hamilton Pierce M.D. | Chief Scientific Officer |
| Mr. Sanjeev Luther | CEO, President & Director |
| Ms. Dorothy J. Clarke | General Counsel |
| Date | Type | Document |
|---|---|---|
| 2026-08-06 | 10-Q | form10-q.htm |
| 2026-07-02 | 8-K | form8-k.htm |
| 2026-06-26 | 8-K | form8-k.htm |
| 2026-05-11 | DEF 14A | formdef14a.htm |
| 2026-05-11 | ARS | formars.pdf |
| 2026-05-11 | 10-Q | form10-q.htm |
| 2026-05-04 | 8-K | form8-k.htm |
| 2026-04-13 | DEF 14C | formdef14c.htm |
| 2026-04-01 | PRE 14C | formpre14c.htm |
| 2026-03-26 | CORRESP | filename1.htm |